🤖 AI Summary
This study addresses a critical limitation of the traditional synthetic control method: when treatment effects are weak, systematic bias can shift the center of confidence intervals, leading to misleading inferences. To remedy this, the authors propose a novel time placebo–guided approach that explicitly quantifies and corrects for such bias. By retrospectively assigning placebo intervention dates within the observed panel and refitting the synthetic control model at each, the method directly estimates the bias distribution under the null hypothesis. This enables the construction of nonparametric confidence intervals calibrated to maintain nominal coverage regardless of the true effect trajectory. The proposed procedure achieves stable, bias-corrected inference with fixed interval width, substantially enhancing the robustness of causal conclusions in synthetic control applications.
📝 Abstract
Synthetic control (SC) methods are among the most widely used tools for causal inference without randomization. The standard Gaussian confidence interval around the estimated effect is simple, fast, and reliably directional when the treatment signal is strong, so practitioners default to it for good reason. Most treated populations, however, are bottom-heavy in intensity, and for them the SC model's systematic bias rivals or exceeds the signal even under good pre-treatment fit. Because this bias shares sign across units it does not average out, and the Gaussian confidence interval shrinks past it and converges on a wrong center. The failure is not imprecision but misdirection: a positive effect estimated as negligible is a missed opportunity, while a negligible effect estimated as significantly positive leads to continued investment in an intervention that is not working. No existing confidence interval for the SC effect measures this bias. We propose a placebo-in-time bootstrap that estimates the bias distribution directly from the observed panel. For each treated unit the procedure backdates the treatment onset and refits the SC model at each placebo onset; the resulting placebo gaps are draws from the same bias distribution that contaminates the real estimate, and bootstrapping them yields a critical value calibrated at the zero null. Because the method resamples realized model error rather than a hypothesized effect, coverage is trajectory-agnostic: it holds at fixed width regardless of how the true effect evolves over time.